Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205126522> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4205126522 endingPage "TPS4170" @default.
- W4205126522 startingPage "TPS4170" @default.
- W4205126522 abstract "TPS4170 Background: Neoadjuvant treatment for potentially curable pancreatic cancer (PDAC) is increasing in acceptability, but a standard regimen has yet to be established. Multiple studies have demonstrated feasibility and effectiveness of the FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin and irinotecan) regimen in the perioperative setting. However, FOLFIRINOX often requires dose modifications, delays and growth factor support due to excessive toxicity which can complicate care delivery when given neoadjuvantly. Liposomal irinotecan injection (Nal-IRI) is FDA approved with a well-tolerated safety profile in relapsed, refractory metastatic PDAC. The current study aims to substitute Nal-IRI for traditional irinotecan in the standard FOLFIRINOX regimen (NALIRIFOX) and to demonstrate safe and effective neoadjuvant delivery. Methods: This phase 2, open-label, multicenter single-arm study focuses on patients (pts) with operable PDAC without metastatic disease. Other key eligibility criteria include age ≥18 years, resectability confirmed by multiD GI tumor board (resectable vs. borderline), adequate cardiac, renal, hepatic function and ECOG performance status of 0 to 1. Pts receive NALIRIFOX regimen as per the table every 2 weeks for four months followed by disease reassessment. Pts who remain surgical candidates will undergo surgical resection within 4 to 8 weeks following last dose of therapy. The primary endpoint is to assess safety and feasibility of regimen in perioperative setting. Secondary endpoints include R0 resection rate, clinical, biochemical and radiological response rate and patient-reported quality of life during treatment as measured by the NCI validated FACT-G scale. Enrollment continues to a maximum of 28 evaluable pts to demonstrate a reduction in historical 30 day postoperative complication rate. NCT03483038. NALIRIFOX regimen components given intravenously (IV) every 14 days. Clinical trial information: NCT03483038. [Table: see text]" @default.
- W4205126522 created "2022-01-26" @default.
- W4205126522 creator A5020154592 @default.
- W4205126522 creator A5020886212 @default.
- W4205126522 creator A5030878684 @default.
- W4205126522 creator A5034958716 @default.
- W4205126522 creator A5039180550 @default.
- W4205126522 creator A5051632076 @default.
- W4205126522 creator A5052737510 @default.
- W4205126522 creator A5059501045 @default.
- W4205126522 creator A5061830119 @default.
- W4205126522 creator A5063221042 @default.
- W4205126522 creator A5066218667 @default.
- W4205126522 creator A5069843364 @default.
- W4205126522 creator A5090416642 @default.
- W4205126522 date "2021-05-20" @default.
- W4205126522 modified "2023-10-14" @default.
- W4205126522 title "A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038)." @default.
- W4205126522 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.tps4170" @default.
- W4205126522 hasPublicationYear "2021" @default.
- W4205126522 type Work @default.
- W4205126522 citedByCount "0" @default.
- W4205126522 crossrefType "journal-article" @default.
- W4205126522 hasAuthorship W4205126522A5020154592 @default.
- W4205126522 hasAuthorship W4205126522A5020886212 @default.
- W4205126522 hasAuthorship W4205126522A5030878684 @default.
- W4205126522 hasAuthorship W4205126522A5034958716 @default.
- W4205126522 hasAuthorship W4205126522A5039180550 @default.
- W4205126522 hasAuthorship W4205126522A5051632076 @default.
- W4205126522 hasAuthorship W4205126522A5052737510 @default.
- W4205126522 hasAuthorship W4205126522A5059501045 @default.
- W4205126522 hasAuthorship W4205126522A5061830119 @default.
- W4205126522 hasAuthorship W4205126522A5063221042 @default.
- W4205126522 hasAuthorship W4205126522A5066218667 @default.
- W4205126522 hasAuthorship W4205126522A5069843364 @default.
- W4205126522 hasAuthorship W4205126522A5090416642 @default.
- W4205126522 hasConcept C121608353 @default.
- W4205126522 hasConcept C126322002 @default.
- W4205126522 hasConcept C141071460 @default.
- W4205126522 hasConcept C143998085 @default.
- W4205126522 hasConcept C203092338 @default.
- W4205126522 hasConcept C2776694085 @default.
- W4205126522 hasConcept C2777148230 @default.
- W4205126522 hasConcept C2780258809 @default.
- W4205126522 hasConcept C2780259306 @default.
- W4205126522 hasConcept C2780962732 @default.
- W4205126522 hasConcept C2781413609 @default.
- W4205126522 hasConcept C526805850 @default.
- W4205126522 hasConcept C535046627 @default.
- W4205126522 hasConcept C71924100 @default.
- W4205126522 hasConceptScore W4205126522C121608353 @default.
- W4205126522 hasConceptScore W4205126522C126322002 @default.
- W4205126522 hasConceptScore W4205126522C141071460 @default.
- W4205126522 hasConceptScore W4205126522C143998085 @default.
- W4205126522 hasConceptScore W4205126522C203092338 @default.
- W4205126522 hasConceptScore W4205126522C2776694085 @default.
- W4205126522 hasConceptScore W4205126522C2777148230 @default.
- W4205126522 hasConceptScore W4205126522C2780258809 @default.
- W4205126522 hasConceptScore W4205126522C2780259306 @default.
- W4205126522 hasConceptScore W4205126522C2780962732 @default.
- W4205126522 hasConceptScore W4205126522C2781413609 @default.
- W4205126522 hasConceptScore W4205126522C526805850 @default.
- W4205126522 hasConceptScore W4205126522C535046627 @default.
- W4205126522 hasConceptScore W4205126522C71924100 @default.
- W4205126522 hasFunder F4320328455 @default.
- W4205126522 hasIssue "15_suppl" @default.
- W4205126522 hasLocation W42051265221 @default.
- W4205126522 hasOpenAccess W4205126522 @default.
- W4205126522 hasPrimaryLocation W42051265221 @default.
- W4205126522 hasRelatedWork W2206740068 @default.
- W4205126522 hasRelatedWork W2410090482 @default.
- W4205126522 hasRelatedWork W2516127020 @default.
- W4205126522 hasRelatedWork W2599910524 @default.
- W4205126522 hasRelatedWork W2883560642 @default.
- W4205126522 hasRelatedWork W2890984767 @default.
- W4205126522 hasRelatedWork W2910998150 @default.
- W4205126522 hasRelatedWork W3159040739 @default.
- W4205126522 hasRelatedWork W3184807956 @default.
- W4205126522 hasRelatedWork W4296207084 @default.
- W4205126522 hasVolume "39" @default.
- W4205126522 isParatext "false" @default.
- W4205126522 isRetracted "false" @default.
- W4205126522 workType "article" @default.